Published in Cancer Immunol Immunother on September 21, 2004
New insights of an old defense system: structure, function, and clinical relevance of the complement system. Mol Med (2010) 1.37
Preoperative systemic inflammation predicts postoperative infectious complications in patients undergoing curative resection for colorectal cancer. Br J Cancer (2009) 1.35
Mannan-binding-lectin-associated serine proteases, characteristics and disease associations. Springer Semin Immunopathol (2005) 1.17
Influence of major surgery on the mannan-binding lectin pathway of innate immunity. Clin Exp Immunol (2006) 0.99
3'-UTR and functional secretor haplotypes in mannose-binding lectin 2 are associated with increased colon cancer risk in African Americans. Cancer Res (2012) 0.99
Mannose-binding lectin deficiency facilitates abdominal Candida infections in patients with secondary peritonitis. Clin Vaccine Immunol (2007) 0.85
Impact of day 2 C-reactive protein on day 3 and 4 thresholds associated with infective complications following curative surgery for colorectal cancer. World J Surg (2013) 0.84
High levels of acute phase proteins and soluble 70 kDa heat shock proteins are independent and additive risk factors for mortality in colorectal cancer. Cell Stress Chaperones (2010) 0.83
Mannose-binding lectin and maladies of the bowel and liver. World J Gastroenterol (2006) 0.79
Circulating mannan-binding lectin, M-, L-, H-ficolin and collectin-liver-1 levels in patients with acute liver failure. Liver Int (2014) 0.76
Mannan-binding lectin-associated serine protease (MASP)-1 is crucial for lectin pathway activation in human serum, whereas neither MASP-1 nor MASP-3 is required for alternative pathway function. J Immunol (2012) 3.86
Collections and ficolins: humoral lectins of the innate immune defense. Annu Rev Immunol (2001) 2.90
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem (2008) 2.44
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst (2002) 2.25
Mannose-binding lectin-deficient mice are susceptible to infection with Staphylococcus aureus. J Exp Med (2004) 2.12
Polymorphisms in innate immunity genes predispose to bacteremia and death in the medical intensive care unit. Crit Care Med (2009) 2.10
Fractionated stereotactic radiotherapy of vestibular schwannomas accelerates hearing loss. Int J Radiat Oncol Biol Phys (2012) 1.99
Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab (2003) 1.93
High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients. Clin Exp Metastasis (2010) 1.87
Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. J Clin Oncol (2009) 1.84
Activation of the lectin pathway by natural IgM in a model of ischemia/reperfusion injury. J Immunol (2006) 1.78
A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur J Haematol (2008) 1.72
L-ficolin is a pattern recognition molecule specific for acetyl groups. J Biol Chem (2004) 1.70
Mannan-binding lectin activates C3 and the alternative complement pathway without involvement of C2. J Clin Invest (2006) 1.69
Effect of capsulation of opportunistic pathogenic bacteria on binding of the pattern recognition molecules mannan-binding lectin, L-ficolin, and H-ficolin. Infect Immun (2005) 1.64
Association between mannose-binding lectin and vascular complications in type 1 diabetes. Diabetes (2004) 1.59
Investigations on the pattern recognition molecule M-ficolin: quantitative aspects of bacterial binding and leukocyte association. J Leukoc Biol (2011) 1.55
Levels of mannan-binding lectin-associated serine protease-2 in healthy individuals. J Immunol Methods (2003) 1.54
Inherited deficiency of mannan-binding lectin-associated serine protease 2. N Engl J Med (2003) 1.52
Survival after radical prostatectomy for clinically localised prostate cancer: a population-based study. BJU Int (2013) 1.46
Multiplexed homogeneous proximity ligation assays for high-throughput protein biomarker research in serological material. Mol Cell Proteomics (2011) 1.39
Regulation of dendritic cells and macrophages by an anti-apoptotic cell natural antibody that suppresses TLR responses and inhibits inflammatory arthritis. J Immunol (2009) 1.39
Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study. Oncol Rep (2007) 1.34
Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Gynecol Oncol (2012) 1.33
Mannan-binding lectin--a soluble pattern recognition molecule. Mol Immunol (2004) 1.28
Banking of biological fluids for studies of disease-associated protein biomarkers. Mol Cell Proteomics (2008) 1.27
MAp44, a human protein associated with pattern recognition molecules of the complement system and regulating the lectin pathway of complement activation. J Immunol (2009) 1.26
Lack of mannose-binding lectin-A enhances survival in a mouse model of acute septic peritonitis. Microbes Infect (2002) 1.26
Serum concentrations of lectin-pathway components in healthy neonates, children and adults: mannan-binding lectin (MBL), M-, L-, and H-ficolin, and MBL-associated serine protease-2 (MASP-2). Pediatr Allergy Immunol (2011) 1.25
Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate (2006) 1.24
Disease-causing mutations in genes of the complement system. Am J Hum Genet (2011) 1.24
Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res (2002) 1.23
C-reactive protein collaborates with plasma lectins to boost immune response against bacteria. EMBO J (2007) 1.19
Characteristics and biological variations of M-ficolin, a pattern recognition molecule, in plasma. J Innate Immun (2009) 1.19
Elevated levels of mannan-binding lectin in patients with type 1 diabetes. J Clin Endocrinol Metab (2003) 1.18
High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival. Cancer (2002) 1.18
Mannan-binding-lectin-associated serine proteases, characteristics and disease associations. Springer Semin Immunopathol (2005) 1.17
MRI, PET/CT and ultrasound in the preoperative staging of endometrial cancer - a multicenter prospective comparative study. Gynecol Oncol (2012) 1.14
L-MBP is expressed in epithelial cells of mouse small intestine. J Immunol (2002) 1.13
Deficiency of mannose-binding lectin greatly increases susceptibility to postburn infection with Pseudomonas aeruginosa. J Immunol (2006) 1.11
Local inflammation induces complement crosstalk which amplifies the antimicrobial response. PLoS Pathog (2009) 1.10
Mannose-binding lectin as a predictor of microalbuminuria in type 1 diabetes: an inception cohort study. Diabetes (2005) 1.10
High serum YKL-40 level in patients with small cell lung cancer is related to early death. Lung Cancer (2004) 1.10
Mannose-binding lectin and mortality in type 2 diabetes. Arch Intern Med (2006) 1.09
Cooperation between MASP-1 and MASP-2 in the generation of C3 convertase through the MBL pathway. Int Immunol (2006) 1.09
Phase I safety, tolerability, and pharmacokinetic study of recombinant human mannan-binding lectin. J Clin Immunol (2006) 1.09
Diagnostic accuracy of C-reactive protein for intraabdominal infections after colorectal resections. J Gastrointest Surg (2009) 1.09
Structural basis for activation of the complement system by component C4 cleavage. Proc Natl Acad Sci U S A (2012) 1.08
Comorbidity is an independent prognostic factor for the survival of ovarian cancer: a Danish register-based cohort study from a clinical database. Gynecol Oncol (2013) 1.08
Serum levels of YKL-40 increases in patients with acute myocardial infarction. Coron Artery Dis (2008) 1.08
The mannan-binding lectin-associated serine proteases (MASPs) and MAp19: four components of the lectin pathway activation complex encoded by two genes. Immunobiology (2002) 1.08
Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer. Clin Cancer Res (2008) 1.08
VEGF and VEGF receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate. Otol Neurotol (2005) 1.07
Cystic fibrosis sputum DNA has NETosis characteristics and neutrophil extracellular trap release is regulated by macrophage migration-inhibitory factor. J Innate Immun (2014) 1.06
Plasma tissue inhibitor of metalloproteinases-1 (TIMP-1): a novel biological marker in the detection of primary colorectal cancer. Protocol outlines of the Danish-Australian endoscopy study group on colorectal cancer detection. Scand J Gastroenterol (2008) 1.06
Complement protein C1q induces maturation of human dendritic cells. Mol Immunol (2007) 1.06
Extracellular protease mRNAs are predominantly expressed in the stromal areas of microdissected mouse breast carcinomas. Carcinogenesis (2005) 1.06
Complement activation and diabetic vascular complications. Clin Chim Acta (2005) 1.06
Circulating VEGF as a biological marker in patients with rheumatoid arthritis? Preanalytical and biological variability in healthy persons and in patients. Dis Markers (2008) 1.04
Biological variations of MASP-3 and MAp44, two splice products of the MASP1 gene involved in regulation of the complement system. J Immunol Methods (2010) 1.03
Diurnal, weekly, and long-time variation in serum concentrations of YKL-40 in healthy subjects. Cancer Epidemiol Biomarkers Prev (2008) 1.01
Biology and potential clinical implications of tissue inhibitor of metalloproteinases-1 in colorectal cancer treatment. Scand J Gastroenterol (2008) 1.01
Preoperative plasma TIMP-1 is an independent prognostic indicator in patients with primary colorectal cancer: a prospective validation study. Eur J Cancer (2010) 1.01
TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid. Clin Cancer Res (2007) 1.00
Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer. Mol Cell Proteomics (2003) 1.00
Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer. Clin Cancer Res (2006) 1.00
Identification of the site of human mannan-binding lectin involved in the interaction with its partner serine proteases: the essential role of Lys55. J Immunol (2007) 0.99
Urokinase plasminogen activator receptor on invasive cancer cells: a prognostic factor in distal gastric adenocarcinoma. Int J Cancer (2011) 0.99
Differential role of the lectin pathway of complement activation in susceptibility to neonatal sepsis. Clin Infect Dis (2010) 0.98
Genetic influences on mannan-binding lectin (MBL) and mannan-binding lectin associated serine protease-2 (MASP-2) activity. Genet Epidemiol (2007) 0.98
The association of reduced folate carrier 80G>A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number. Blood (2010) 0.98
YKL-40 tissue expression and plasma levels in patients with ovarian cancer. BMC Cancer (2009) 0.97
Mannan-binding lectin deficiency modulates the humoral immune response dependent on the genetic environment. Immunology (2009) 0.97
Toward a structure-based comprehension of the lectin pathway of complement. Mol Immunol (2013) 0.96
Early posttransplant serum osteoprotegerin levels predict long-term (8-year) patient survival and cardiovascular death in renal transplant patients. J Am Soc Nephrol (2006) 0.95
Human H-ficolin inhibits replication of seasonal and pandemic influenza A viruses. J Immunol (2012) 0.95
New perspectives on mannan-binding lectin-mediated complement activation. Immunobiology (2007) 0.95
Data fusion in metabolomic cancer diagnostics. Metabolomics (2012) 0.95
Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan. APMIS (2010) 0.95
Indication of a role of plasminogen activator inhibitor type I in protecting murine fibrosarcoma cells against apoptosis. Thromb Haemost (2005) 0.94
Expression level of Wilms tumor 1 (WT1) protein has limited prognostic value in epithelial ovarian cancer: from the Danish "MALOVA" ovarian cancer study. Gynecol Oncol (2007) 0.94
Detection of serological biomarkers by proximity extension assay for detection of colorectal neoplasias in symptomatic individuals. J Transl Med (2013) 0.94
Syncytin immunoreactivity in colorectal cancer: potential prognostic impact. Cancer Lett (2009) 0.93
Lack of the pattern recognition molecule mannose-binding lectin increases susceptibility to influenza A virus infection. BMC Immunol (2010) 0.93
Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival. Clin Cancer Res (2007) 0.93
Oxidative stress sensitizes retinal pigmented epithelial (RPE) cells to complement-mediated injury in a natural antibody-, lectin pathway-, and phospholipid epitope-dependent manner. J Biol Chem (2013) 0.92
Rapid and individual-specific glycoprofiling of the low abundance N-glycosylated protein tissue inhibitor of metalloproteinases-1. Mol Cell Proteomics (2007) 0.92
Mechanisms of topoisomerase I (TOP1) gene copy number increase in a stage III colorectal cancer patient cohort. PLoS One (2013) 0.92